334769-80-1

Basic information

• Product Name: (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid
• Synonyms: (2s,5s)-n-boc-5-methylpyrrolidine-2-carboxylic acid;(2S,5S)- 5-Methyl-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester;(2S,5S)-1-(tert-Butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid;(2S,5S)-N-Boc-5-Methylpyrrolidine-2-carboxylic aci;GS-5817 interMediate;2. (2S,5S)-1-(tert-butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid;(2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid(2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid;(2S,5S)-5-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid
• CAS NO: 334769-80-1
• Molecular Formula: C₁₁H₁₉NO₄
• Molecular Weight: 229.27
• Mol File: 334769-80-1.mol

Chemical Properties

• Boiling Point: 343.2 °C at 760 mmHg
• Flash Point: 161.4 °C
• Appearance: /
• Density: 1.150
• Refractive Index: 1.49
• Storage Temp.: 2-8°C
• PKA: 4.02±0.40(Predicted)
• CAS DataBase Reference: (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid(334769-80-1)
• EPA Substance Registry System: (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid(334769-80-1)

Safety Data

• Hazardous Substances Data: 334769-80-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid serves as a key intermediate in the synthesis of various pharmaceuticals. Its unique stereochemistry and functional groups make it a valuable component in the creation of complex drug molecules, contributing to the development of new treatments for a range of medical conditions.
Used in Organic Synthesis:
As a chiral building block, (2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid is utilized in the synthesis of enantiomerically pure compounds, which are essential in various chemical reactions. Its presence ensures the preservation of stereochemistry, leading to the production of desired enantiomers with specific biological activities.
Used in the Synthesis of Biologically Active Molecules:
(2S,5S)-N-Boc-5-methylpyrrolidine-2-carboxylic acid is employed as a precursor in the preparation of biologically active molecules, such as peptides, alkaloids, and other natural products. Its versatility and chiral properties enable the creation of molecules with specific biological functions, potentially leading to the discovery of new therapeutic agents and diagnostic tools.

InChI:InChI=1/C11H19NO4/c1-7-5-6-8(9(13)14)12(7)10(15)16-11(2,3)4/h7-8H,5-6H2,1-4H3,(H,13,14)/t7-,8-/m0/s1

Upstream product

• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 113400-36-5 benzyl (2S)-N-tert-butoxycarbonyl-5-oxoprolinate 
• 4931-66-2 methyl (S)-pyroglutamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 38533-38-9 (5S,2S)-(-)-5-methylproline 
• 98-79-3 L-Pyroglutamic acid 
• 94885-52-6 benzyl (L)-pyroglutamate 
• 54824-06-5 C₁₃H₁₇NO₂ 
• 113400-46-7 benzyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-oxohexanoate 
• 915157-02-7 (2S,5S)-methyl 5-methylpyrrolidine-2-carboxylate 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 676560-84-2 (2S,5S)-5-methylpyrrolidine-2-carboxylic acid ethyl ester 
• 913251-58-8 (S)-2-(tert-butoxycarbonylamino)-5-oxohexanoic acid ethyl ester 

Downstream Products

• 1250939-12-8 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester 
• 1335316-41-0 2-[2-[4-(4-bromophenyl)phenyl]-2-oxo-ethyl]-1-tert-butyl-(2S,5S)-5-methylpyrrolidine-1,2-dicarboxylate 
• 1433280-49-9 4-(4-bromo-phenyl)-2-((2S,5S)-5-methyl-pyrrolidin-2-yl)-1H-imidazole 
• 1378390-49-8 ((S)-1-{(2S,5S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-5-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1433280-50-2 [(S)-2-methyl-1-((2S,5S)-2-methyl-5-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]carbamic acid methyl ester 
• 1378390-49-8 C₂₁H₂₇BrN₄O₃ 
• 1433280-50-2 methyl ((S)-3-methyl-1-((2S,5S)-2-methyl-5-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamate 
• 1033709-37-3 (5S)-1-{[(5R,6S)-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]carbonyl}-N,N,5-trimethyl-L-prolinamide 
• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1844064-96-5 (2S,4S)-2-[5-(2-{(2S,4S)-1-{N-(methoxycarbonyl)-L-valyl}-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromene[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine 
• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 38533-38-9 (5S,2S)-(-)-5-methylproline 
• 1377050-12-8 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-methylpyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1378392-97-2 methyl [(2S)-3-methyl-1-{(2S,5S)-2-methyl-5-[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-1-yl}-1-oxobutan-2-yl]carbamate 

Relevant articles and documents

Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof

The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.

Deuterated antiviral active compounds for hepatitis C viruses

The invention relates to antiviral compounds for hepatitis C viruses (HCVs) and nontoxic pharmacologically-acceptable salts thereof, wherein the compounds are represented by a formula I shown in the description and have good bioavailability, and the compounds have potent inhibiting effects on the all-genotypic HCVs. In the structural formula I, R1, R2, R3 and R4 are independently selected from methyl (-CH3) or deuterated methyl (-CD3); X1, X2, X3, X4 and X5 are separately hydrogen (H) or deuterium (D); and one of the R1, the R2, the R3 and the R4 must be deuterated methyl (-CD3) or one of theX1, the X2, the X3, the X4, and the X5 must be deuterium (D).

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.

ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or harmaceutical com ositions thereof in the treatment of HCV infection or he atitis C.

Flexible and modular syntheses of enantiopure 5-cis-substituted prolinamines from l-pyroglutamic acid

A wide range (25 examples) of 5-cis-substituted prolinamines is prepared in five to ten steps starting from cheap l-pyroglutamic acid. Three routes, differing mainly in the order of introduction of the substituents at the 5-cis position, the pyrrolidine nitrogen atom, and the exocyclic amino function, are successfully developed.

ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.